Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HCW BiologicsHCWB -14.63%37 Days Sales Outstanding is 31.20 as of Jun. 2026, which is 79% below its 10-year median of 150.58. GuruFocus rates HCWB with a GF Score™ of 37/100 and a GF Value™ of $35.26 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, HCW Biologics ranks better than 98.57% on this metric.
HCW Biologics's average Accounts Receivable for the
three
months ended in Jun. 2026 was $0.05 Mil. HCW Biologics's Revenue for the
three
months ended in Jun. 2026 was $0.14 Mil.
Hence, HCW Biologics's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 31.20.
The historical rank and industry rank for HCW Biologics's Days Sales Outstanding or its related term are showing as below:
HCWB'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.93 Med: 150.58 Max: 2075.09
Current: 1.93
During the past 7 years, HCW Biologics's highest Days Sales Outstanding was 2075.09. The lowest was 1.93. And the median was 150.58.
HCWB's Days Sales Outstanding is ranked better than 98.57% of 841
companies
in the Biotechnology industry
Industry Median: 68.94
vs HCWB: 1.93
HCW Biologics's Days Sales Outstanding
declined
from Jun. 2025 (710.45) to Jun. 2026 (31.20).
HCW Biologics (NAS:HCWB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
HCW Biologics Days Sales Outstanding Related Terms
HCW Biologics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for HCW Biologics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCWB vs AAGH, ACXP, ENVB: Days Sales Outstanding Comparison
For the Biotechnology subindustry, HCW Biologics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where HCW Biologics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a Days Sales Outstanding of 31.20 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on HCW Biologics and its competitors. This is 79% below median its historical median of 150.58. Over the past decade, HCW Biologics' Days Sales Outstanding has ranged from 1.93 to 2,075.09. According to the industry distribution chart, HCW Biologics ranks #12 out of 841 companies in the Biotechnology industry, placing it in the top 1.4%.
Is HCW Biologics' Days Sales Outstanding too high?
HCW Biologics' current Days Sales Outstanding of 31.20 is 79% below median its 10-year median of 150.58. Over the past 10 years, this metric has ranged from a low of 1.93 to a high of 2,075.09. The Biotechnology industry median Days Sales Outstanding is 68.94. HCW Biologics' value of 31.20 is 54.7% below this industry median. Based on the distribution chart, HCW Biologics ranks #12 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HCW Biologics has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Days Sales Outstanding compare to AAGH and ACXP?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #12 out of 841 companies for Days Sales Outstanding. This places HCW Biologics in the top 1% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 68.94. HCW Biologics' value of 31.20 is 54.7% below this benchmark. Historically, HCW Biologics' own Days Sales Outstanding has ranged from 1.93 to 2,075.09 over the past decade. While the company's 10-year median is 150.58 vs. the industry median of 68.94, HCW Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current Days Sales Outstanding of 31.20 is 54.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current Days Sales Outstanding is 31.20, which is 79% below median its own 10-year median of 150.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $35.26, compared to a current price of $2.45 — trading 93.1% below its estimated fair value. The current Days Sales Outstanding is 31.20, which is 79% below median its 10-year median of 150.58 and 54.7% below the Biotechnology industry median of 68.94. HCW Biologics' overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Days Sales Outstanding is 31.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $2.45 is trading 93.1% below its estimated GF Value™ of $35.26.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
Days Sales Outstanding: 31.20 (79% below median its 10-year median of 150.58)
GF Value™: $35.26 vs. price of $2.45 (93.1% below fair value)
Industry Position: 54.7% below the Biotechnology median (#12 of 841)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
37GF Score
Get the complete analysis for HCWB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
